Alpha Teknova, Inc.

TKNO

Nasdaq; healthcare; SIC 2835, In Vitro & In Vivo Diagnostic Substances; CIK 0001850902

D

fourth fifth of 369 graded peers in healthcare

rank 250 of 369; percentile 67.7; sampling error 2.5 points; lower is stronger

A B C D E

D, the sloth



Scoreboard

Profitability	D percentile 69.1
Solvency	B/C percentile 41.0
Growth and financing	C percentile 53.4
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $103.6M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered
Inputs computable	9 of 14
Graded from	filings received through Mar 2, 2026 244 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026
Last close	$7.33 2026-10-30; market equity $393.3M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 2, 2026

Alpha Teknova, Inc. (referred to herein as the Company, Teknova, we, us or our) is a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Our more than 3,000 customers span the continuum of the life sciences market and include leading pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostics franchises, and academic and government research institutions. Our Company is built around our knowledge, methods, and know-how in our manufacturing processes and infrastructure, which are highly adaptable and configurable.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 69.1						
Gross profitability	13.0%	32.4%		72.3	366	2025-12-31
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

pretax income must exceed the validity floor and imply a 0%-100% tax rate						
Accruals ratio	(7.7%)	(6.6%)		50.9	803	2025-12-31
Gross margin stability, five years	10.1 pts	2.8 pts		84.2	242	2025-12-31
Solvency, sleeve percentile 41.0						
Twelve-month failure probability	0.06%	0.08%		39.6	246	2026-06-30
Altman Z double-prime	(1.59)	(0.35)		43.6	748	2025-12-31
Net debt to EBITDA	not computable	1.82x				
EBITDA must exceed $100,000						
Interest coverage	not computable	(4.51x)				
one or more required annual facts are missing						
Current ratio	4.58x	2.92x		39.7	829	2025-12-31
Growth and financing, sleeve percentile 53.4						
Revenue growth, three-year compound	(0.7%)	10.1%		73.2	412	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%				
current FCF must be positive and base FCF must exceed $100,000						
Reinvestment rate	not computable	37.1%				
pretax income must exceed the validity floor and imply a 0%-100% tax rate						
Asset growth, three years	(12.1%)	2.2%		71.8	696	2025-12-31
Net share issuance, one year	0.3%	2.5%		15.2	631	2026-02-27

Among 369 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
245	Exagen Inc. (XGN)	66.3	D	dilution, fortress balance sheet
246	Amylyx Pharmaceuticals, Inc. (AMLX)	66.6	D	short runway, degenerate inputs
247	Cardiff Oncology, Inc. (CRDF)	66.8	D	short runway, fortress balance sheet
248	Lyell Immunopharma, Inc. (LYEL)	67.1	D	dilution, degenerate inputs
249	PTC Therapeutics, Inc. (PTCT)	67.4	D	
250	Alpha Teknova, Inc. (TKNO)	67.7	D	
251	U S Physical Therapy Inc. (USPH)	67.9	D	
252	Iovance Biotherapeutics, Inc. (IOVA)	68.2	D	dilution, short runway
253	American Shared Hospital Services (AMS)	68.5	D	late filer
254	Orchestra BioMed Holdings, Inc. (OBIO)	68.8	D	dilution, short runway, fortress balance sheet
255	Adaptive Biotechnologies Corp. (ADPT)	69.0	D	

What the price implies

at the 2026-10-30 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	69.5%	(2.2%)	83
Distance from 52-week high	(21.1%)	(28.7%)	60
EBIT to enterprise value	(4.2%)	(1.4%)	44

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Free cash flow yield	(2.5%)	(1.0%)	46
Book value to price	0.16	0.28	35
Sales to price	0.10	0.30	26
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	0.36	(0.19)	83

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 5 of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$6.0M
Operating cash flow, four quarters	-$6.3M
Months of runway	11.5
Days since last periodic filing	87 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	$2.3M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$13.4M	2025-12-31	2026-03-02	10-K	26-000002
2	assets	us-gaap:Assets	$103.6M	2025-12-31	2026-03-02	10-K	26-000002
3	operating income	us-gaap:OperatingIncomeLoss	-$17.0M	2025-12-31	2026-03-02	10-K	26-000002
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$17.2M	2025-12-31	2026-03-02	10-K	26-000002
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$58,000	2025-12-31	2026-03-02	10-K	26-000002
6	total debt	us-gaap:LongTermDebt	$13.1M	2025-12-31	2026-03-02	10-K	26-000002
7	book equity	us-gaap:StockholdersEquity	$68.8M	2025-12-31	2026-03-02	10-K	26-000002
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$5.9M	2025-12-31	2026-03-02	10-K	26-000002
9	total debt	us-gaap:LongTermDebt	$9.4M	2024-12-31	2026-03-02	10-K	26-000002
10	book equity	us-gaap:StockholdersEquity	$82.4M	2024-12-31	2026-03-02	10-K	26-000002
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$3.7M	2024-12-31	2026-03-02	10-K	26-000002
12	net income	us-gaap:NetIncomeLoss	-$17.3M	2025-12-31	2026-03-02	10-K	26-000002
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$8.6M	2025-12-31	2026-03-02	10-K	26-000002
14	assets	us-gaap:Assets	$118.8M	2024-12-31	2026-03-02	10-K	26-000002
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$40.5M	2025-12-31	2026-03-02	10-K	26-000002
16	gross profit	us-gaap:GrossProfit	$7.2M	2024-12-31	2026-03-02	10-K	26-000002
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$37.7M	2024-12-31	2026-03-02	10-K	26-000002
18	gross profit	us-gaap:GrossProfit	$10.3M	2023-12-31	2025-03-07	10-K	25-035705
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$36.7M	2023-12-31	2025-03-07	10-K	25-035705
20	gross profit	us-gaap:GrossProfit	$17.5M	2022-12-31	2024-03-27	10-K	24-036624
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$41.4M	2022-12-31	2024-03-27	10-K	24-036624
22	gross profit	us-gaap:GrossProfit	$17.6M	2021-12-31	2023-03-30	10-K	23-010926
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$36.9M	2021-12-31	2023-03-30	10-K	23-010926
24	current assets	us-gaap:AssetsCurrent	$34.5M	2025-12-31	2026-03-02	10-K	26-000002
25	current liabilities	us-gaap:LiabilitiesCurrent	$7.5M	2025-12-31	2026-03-02	10-K	26-000002

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$135.8M	2025-12-31	2026-03-02	10-K	26-000002
27	liabilities	us-gaap:Liabilities	$34.8M	2025-12-31	2026-03-02	10-K	26-000002
28	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$6.3M	2025-12-31	2026-03-02	10-K	26-000002
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.1M	2025-12-31	2026-03-02	10-K	26-000002
30	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$12.4M	2024-12-31	2026-03-02	10-K	26-000002
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.1M	2024-12-31	2026-03-02	10-K	26-000002
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$18.8M	2023-12-31	2025-03-07	10-K	25-035705
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$7.9M	2023-12-31	2025-03-07	10-K	25-035705
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$27.4M	2022-12-31	2024-03-27	10-K	24-036624
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$28.1M	2022-12-31	2024-03-27	10-K	24-036624
36	current assets	us-gaap:AssetsCurrent	$42.8M	2024-12-31	2026-03-02	10-K	26-000002
37	current liabilities	us-gaap:LiabilitiesCurrent	$11.2M	2024-12-31	2026-03-02	10-K	26-000002
38	assets	us-gaap:Assets	$128.6M	2023-12-31	2025-03-07	10-K	25-035705
39	assets	us-gaap:Assets	$152.3M	2022-12-31	2024-03-27	10-K	24-036624
40	shares outstanding	dei:EntityCommonStockSharesOutstanding	53,587,662	2026-02-27	2026-03-02	10-K	26-000002
41	shares outstanding	dei:EntityCommonStockSharesOutstanding	53,436,806	2025-03-05	2025-03-07	10-K	25-035705

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.